Glutaminergic Transmission in Autism : Molecular Imaging Exploration
NCT ID: NCT02719951
Last Updated: 2025-12-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
27 participants
INTERVENTIONAL
2016-04-30
2019-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
autistic patients
\[18F\]FPEB PET imaging MRI (Magnetic Resonance Imaging) Biological samples
[18F]FPEB PET imaging
PET exam
Biological samples
blood sample and urine sample
MRI
MRI exam
FXS patients
\[18F\]FPEB PET imaging MRI Biological samples
[18F]FPEB PET imaging
PET exam
Biological samples
blood sample and urine sample
MRI
MRI exam
Healthy subjects
\[18F\]FPEB PET imaging MRI Biological samples
[18F]FPEB PET imaging
PET exam
Biological samples
blood sample and urine sample
MRI
MRI exam
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
[18F]FPEB PET imaging
PET exam
Biological samples
blood sample and urine sample
MRI
MRI exam
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Between 18 years-old and 45 years-old
* Informed, written consent obtained from patient or his representant
* Subject with an affiliation to French social security
* For autistic patient : patient with diagnosis of ASD (Autistic Spectrum Disorders) following DSM-IV or DSM-5 criteria with recommended tools (ADI-R and/or ADOS)
* For FXS patient : diagnosis of FXS and confirmation of total mutation of FMR1
Exclusion Criteria
* Excessive use of alcohol or drug, or addiction to alcohol or drug during last 6 months
* Any unstable or uncontrolled disease, clinically significant
* Participation to an other experimental protocol with drug or irradiant exam
* Person under exclusion period because of previous participation to an other experimental protocol
* Person under temporary guardianship
* Forbidden treatments : any psychotropic treatment for 4 last weeks before PET exam and changing durably glutaminergic transmission directly or undirectly
* For healthy subjects : adult under guardianship, medical history of central nervous system disease, medical history of attention deficit hyperactivity disorder, past or present psychiatric or neurologic disorder (MINI DSM-IV)
18 Years
45 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Tours
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Tours
Tours, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Dupont AC, Serriere S, Barantin L, Vercouillie J, Tauber C, Gissot V, Bodard S, Chicheri G, Chalon S, Bonnet-Brilhault PF, Santiago-Ribeiro PM, Arlicot N. Study of influence of the glutamatergic concentration of [18F]FPEB binding to metabotropic glutamate receptor subtype 5 with N-acetylcysteine challenge in rats and SRM/PET study in human healthy volunteers. Transl Psychiatry. 2021 Jan 20;11(1):66. doi: 10.1038/s41398-020-01152-2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRIA 14 FBB / TANGAU
Identifier Type: -
Identifier Source: org_study_id